00:47 , Feb 16, 2019 |  BC Extra  |  Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
15:55 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
11:00 , Nov 15, 2018 |  BC Extra  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
17:40 , Mar 17, 2017 |  BC Week In Review  |  Company News

Ataxion, Luc Therapeutics deal

Ataxion will merge with Luc; the newco will retain Luc's name and focus on precision medicine for neurological and psychiatric diseases. Its pipeline includes programs to treat ataxia, schizophrenia and depression, which is being developed...
07:00 , Jun 27, 2016 |  BioCentury  |  Emerging Company Profile

Next-gen NMDA

Naurex Inc. spinout Aptinyx Inc. has a discovery platform and preclinical pipeline of oral small molecule NMDA receptor modulators for CNS disorders that could enhance synaptic plasticity and avoid the adverse events associated with NMDA...
01:19 , Oct 7, 2015 |  BC Extra  |  Company News

Management tracks

Neurology company Rodin Therapeutics Inc. (Cambridge, Mass.) named Adam Rosenberg CEO. Rosenberg was CEO of Teleos Therapeutics (Medford, Mass.). Oncology play Tracon Pharmaceuticals Inc. (NASDAQ:TCON) named Ronald Shazer CMO. Shazer was senior director and clinical...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Company News

Mnemosyne management update

Mnemosyne Pharmaceuticals Inc. , Providence, R.I.   Business: Neurology   Hired: Vanessa King as president and CEO, formerly executive director of external R&D and head of external venture innovation at Amgen Inc. ; she succeeds...
07:00 , Sep 12, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Epilepsy NMDAR; NMDA receptor NR2A subtype (GRIN2A; NR2A) Human genetic and cell culture studies suggest modulating NMDARs could be useful for...
07:00 , Sep 5, 2013 |  BC Innovations  |  Targets & Mechanisms

Epilepsy narrows down

A spate of human genetic studies has shed light on the root causes of idiopathic focal epilepsy, a common childhood form of the disease. The studies suggest that a group of epilepsies and encephalopathies marked...